Aura Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA) CEO to participate in investor conferences, including Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Live webcasts and replays available on the company's website.

BOSTON--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

• Jefferies London Healthcare Conference on Wednesday, November 15, 2023.
  Presentation at 9:30 a.m. ET.
• 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023.
  Fireside Chat at 4:15 p.m. ET.

The live webcasts of the presentation and fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing VDCs, a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting, anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura has initiated activities for the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where the standard of care with radiotherapy leaves patients with severe comorbidities, including significant vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive and muscle invasive bladder cancer. Aura is headquartered in Boston, MA.

For more information, visit aurabiosciences.com, or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108003026/en/

Investors and Media:

Alex Dasalla

Head of Investor Relations and Corporate Communications

adasalla@aurabiosciences.com

Source: Aura Biosciences Inc.

FAQ

What is the latest announcement from Aura Biosciences Inc. (NASDAQ: AURA)?

The CEO will participate in upcoming investor conferences, including Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.

When and where will the CEO be presenting at the conferences?

The CEO will present at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023, at 9:30 a.m. ET and at the Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 4:15 p.m. ET.

Where can the webcasts of the presentations be accessed?

The live webcasts will be available on the 'Investors & Media' page under the 'Events & Presentations' section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, with replays archived for 90 days following the presentation date.